BAG3 receptor binding molecules for use as a medicament
The present invention relates to the use of BAG3 receptor-binding molecules as a medicament, in particular for use in the treatment of diseases of an immune, inflammatory, cardiovascular, neoplastic and/or degenerative nature.
1. A method for treating pancreatic cancer in a subject, comprising the step of administering to the subject a pharmaceutical composition comprising at least one BAG3 (Bcl2-associated athanogene 3) receptor-binding molecule that binds to IFITM-2 protein (interferon-induced transmembrane protein 2) and at least one pharmaceutically acceptable excipient, wherein said molecule is an antibody that binds IFITM-2 or an antigen-binding fragment thereof and inhibits the binding of BAG3 to the BAG3 receptor.
2. The method according to claim 1 , wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of: polyclonal antibodies, monoclonal antibodies, mouse antibodies, humanized antibodies, chimeric antibodies, recombinant antibodies, conjugated antibodies, scFv fragments, Fab fragments, and F(ab′) 2 fragments.
3. The method according to claim 2 , wherein said antibody is an anti-IFITM-2 antibody.
4. The method according to claim 1 , wherein said subject is a human.
5. A method for treating pancreatic cancer, comprising the step of administering to the subject a BAG3 receptor-binding molecule that binds to IFITM-2 protein, wherein said molecule is an antibody that binds IFITM-2 or an antigen-binding fragment thereof and inhibits the binding of BAG3 to the BAG3 receptor.
6. The method according to claim 5 , wherein said BAG3 receptor is expressed on the surface of macrophages.
7. The method according to claim 5 , wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of: polyclonal antibodies, monoclonal antibodies, mouse antibodies, humanized antibodies, chimeric antibodies, recombinant antibodies, conjugated antibodies, scFv fragments, Fab fragments, and F(ab′) 2 fragments.
8. The method according to claim 5 , wherein said antibody is an anti-IFITM-2 antibody.
9. The method according to claim 5 , wherein said subject is a human.
10. A method of inhibiting the binding of BAG3 to macrophages, comprising the step of contacting macrophages with a BAG3 receptor-binding molecule that binds to IFITM-2 protein, wherein said molecule is an antibody or antigen-binding fragment thereof that binds IFITM-2 and inhibits the binding of BAG3 to the BAG3 receptor.
11. The method of claim 10 , wherein said method is carried out in vitro.
12. The method of claim 10 , wherein said method is carried out in vivo in a subject.
13. The method of claim 12 , wherein said subject suffers from pancreatic cancer.
14. The method of claim 1 , further comprising administering a pharmaceutical composition comprising at least one anti-BAG3 antibody and a pharmaceutically acceptable excipient.
15. The method of claim 14 , wherein administering said pharmaceutical composition comprising an antibody that binds IFITM-2 or antigen-binding fragment thereof and a pharmaceutically acceptable excipient and administering said pharmaceutical composition comprising an anti-BAG3 antibody and a pharmaceutically acceptable excipient are simultaneous, separate, or sequential.
16. The method of claim 5 , further comprising administering at least one anti-BAG3 antibody.
17. The method of claim 16 , wherein administering said antibody that binds IFITM-2 or antigen-binding fragment thereof and administering said anti-BAG3 antibody are simultaneous, separate, or sequential.